The backtest results for ABVX following earnings beats show poor short-term performance with 0% win rates at 3 and 10 days and negative returns of -12.07% and -21.09%, respectively. However, the 30-day win rate improves to 50% with a slight negative return of -1.23%, indicating some recovery over a longer horizon. This suggests that immediate reactions to earnings beats may be unfavorable, but the stock could stabilize or improve moderately over a month. Investors should be cautious about short-term exposure and consider a longer-term perspective when trading ABVX post-earnings beat.

backtest_data

The backtest results for ABVX show a consistent 50% win rate across 3, 10, and 30 days following earnings misses, with returns improving over time, reaching 22.72% at 30 days. This indicates a mixed short-term reaction but a notable positive rebound in the longer term. The maximum return of 74.04% occurring on day 33 suggests significant upside potential after initial setbacks. Investors might consider that despite earnings misses, ABVX can recover strongly, highlighting opportunities for strategic entry post-earnings disappointment.

The backtest results show that the Biotechnology Industry experienced a slight negative impact following earnings beats, with a maximum return of only 0.29% observed 15 days after the event. This suggests that despite positive earnings surprises, the sector does not significantly benefit in the short to medium term. The minimal positive return indicates limited upside potential from earnings beats alone.

This outcome implies that investors should be cautious about expecting strong gains solely based on earnings beats in the Biotechnology Industry. It may be prudent to consider additional factors beyond earnings surprises when making investment decisions in this sector.

The backtest results show that earnings misses in the Biotechnology Industry have no significant impact, with a maximum return of -0.08% observed three days after the event. This negligible effect suggests that the industry’s stock prices are largely resilient to earnings disappointments over the tested period.

The analysis indicates that investors may not need to adjust their positions based solely on earnings misses within this sector, as the market reaction is minimal and short-lived.

Therefore, investment strategies should consider other factors beyond earnings misses when evaluating Biotechnology stocks.

Backtest ABVX Release Earning Report

Find all upcoming company earnings reports scheduled for mar 23 2026. Get details on which companies are reporting and their expected results.

Calendar